Background: H2-histamine receptors mediate a wide range of physiological functions extending from stimulation of gastric acid secretion to induction of human promyelocyte differentiation. We have previously cloned the H2-histamine receptor gene and noted that only three amino acids on the receptor were sufficient to define its specificity and selectivity. Despite only modest overall amino acid homology (34% amino acid identity and 57.5% similarity) between the H2-histamine receptor and the receptor for another monoamine, the ,B2-adrenergic receptor, there is remarkable similarity at their critical ligand binding sites. We hypothesized that, if the specificity and selectivity of both receptors are invested in just three amino acids, it should be possible to convert one of the receptors into one that recognizes the ligand of the other by simple mutations at only one or two sites.
INTRODUCTION
The availability of genes encoding an increasingly wide array of receptors for regulatory substances has led to insight into the molecular basis of ligand-receptor interactions. Recently, we cloned the H2 -histamine receptor gene (1) and noted that only three amino acids on the receptor were sufficient to define the specificity and selectivity of the receptor (2) . By extrapolation of these findings, it is conceivable that ligand specificity is determined by only a few key points on a receptor regardless of the structure of the remainder of the molecule. We have previously 
METHODS

Mutagenesis and Expression
For our studies, the canine H2-histamine receptor gene was subcloned into the sequencing vector Ml 3 and used as a template for the synthesis of DNA with specific mutations according to the method of Kunkel (5) . A polymerase chain reaction (PCR) strategy was used to subclone the coding region of both the wild-type and mutated H2-histamine receptors into the eukaryotic expression vector CMVneo, as previously described (2, 6) . Hepa cells (derived from a rat hepatoma) and L cells (derived from a mouse fibroblast-like cell) were then transfected with the receptor/ CMVneo constructs by calcium phosphate coprecipitation (7) and clones were selected in media containing the neomycin analogue G-418 
RESULTS
As shown in Fig. 2 , epinephrine, the catecholamine used in these studies, dose-dependently stimulated the production of cyclic 3',5'-adenosine monophosphate (cAMP) in nontransfected ceptor, the Hepa cells demonstrated, once again, a biphasic response. However, in this instance, the initial phase was greatly exaggerated and, in contrast to the effect obtained with the wild-type H2-histamine receptor, inhibited with either cimetidine or propranolol. As depicted in Fig. 3 membrane inositol phospholipids and mobilize intracellular calcium (9) . Accordingly, to verify that the catecholamine response that we were observing in the Hepa cells transfected with the Ala'86-Ser187 mutant H2-histamine receptor was a result of action at the mutant histamine receptor and not the endogenous catecholamine receptor, we examined the effect of epinephrine on membrane inositol phospholipid turnover as measured by the production of IP3. As shown in Histamine (-log M) receptors. For example, the alteration of a single amino acid has been shown to account for the pharmacological differences between the rat and human 5-hydroxytryptamine lB receptors (10, 11) and the canine and human cholecystokinin-B/gastrin receptors (12) . Similarly, a point mutation in the a2-adrenergic or 5-hydroxytryptamine 1A receptors changes their affinity for 13-adrenergic receptor antagonists (13, 14) . In other studies the receptors for the tachykinins substance P (NK1 receptor) and neurokinin B (NK3 receptor) have been shown to exhibit alterations in receptor binding affinity to nonpeptide antagonists as a result of changes in only one or two of its amino acid residues (1 5-17) . Our experiments provide the first demonstration that such minor amino acid changes can result in changes in ligand specificity so major that they can cross the gap between entire families of receptors that have only modest structural homology. These findings have important implications in the design of pharmacological agents that are directed at physiological receptors. It is possible, for example, that so-called specific receptor antagonists or agonists may have crossover effects on other groups of receptors that would not be predicted on the basis of overall structural homology. Moreover, it may be possible to utilize unique agonists or antagonists for targeting ligand delivery to artificially constructed mutant receptors that are transfected into various tissues in the body.
